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S U M M A R Y
Objective: To estimate the infection prevalence in Buenos Aires during the outbreak of pandemic
inﬂuenza A/H1N1 2009 virus (A(H1N1)pdm09).
Methods: A(H1N1)pdm09-speciﬁc antibodies were measured by hemagglutination inhibition assay in
human serum samples collected 6 months after the outbreak and before the introduction of the
A(H1N1)pdm09 vaccine in Argentina. Baseline levels of cross-reactive antibodies to A(H1N1)pdm09
were determined by testing 162 serum samples collected before 2009.
Results: The overall seroprevalence of A(H1N1)pdm09 in 150 children and 427 adults was 28.9% (95%
conﬁdence interval (CI) 25–33%), with a 58.0% prevalence in children <19 years of age and an 18.7%
prevalence in adults 19 years of age (p < 0.001). The prevalence was 43.5% in children <5 years old and
60.6% among children aged 5–18 years. The prevalence in adults declined with increasing age: 24.9% in
19–39-year-olds, 9.7% in 40–59-year-olds, and 8.1% in those 60 years old. The prevalence of speciﬁc
A(H1N1)pdm09 antibodies was higher compared with the baseline in children (p = 0.014), adolescents
(p < 0.001), and adults <40 years old (p = 0.017). Seroprevalence in health care workers was not different
from the rest of the population (13.6% vs. 19.3%, respectively; p = 0.421).
Conclusions: The prevalence of speciﬁc A(H1N1)pdm09 antibodies was high at 28.9%. The highest
prevalence was observed in children, adolescents, and young adults.
 2013 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious
Diseases. 
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At the end of March 2009, during the early spring, an outbreak
of illness caused by a novel swine-origin inﬂuenza A/H1N1 virus
was identiﬁed in Mexico;1 this constituted the ﬁrst wave of
the outbreak that was less severe than the second wave in
the Northern Hemisphere.2,3 In June 2009, the World Health     
§§ Presented as an abstract ‘‘Inﬂuenza A (H1N1) 2009 seroprevalence in residents
of the metropolitan area and suburbs in Buenos Aires, Argentina (MASBA)’’ at the
107th International Conference of the American Thoracic Society, Denver, Colorado,
USA, May 13–18, 2011.
* Corresponding author. Tel./Fax: +54 (0)11 4821 4407.
E-mail addresses: dr.cm.luna@gmail.com, cymluna@yahoo.com (C.M. Luna).
1201-9712       2013 The Authors. Published by Elsevier Ltd on behalf of International So
http://dx.doi.org/10.1016/j.ijid.2013.09.021Organization (WHO) declared that the rapidly spreading swine-
origin inﬂuenza A/H1N1 virus constituted a global pandemic.4
Many countries made detailed plans to mitigate the clinical and
societal effects of the pandemic. The A(H1N1)pdm09 virus caused
over 277 607 laboratory-conﬁrmed cases and over 3205 deaths
worldwide as of September 6, 2009,5 but national and interna-
tional authorities have acknowledged that these counts are
substantial underestimates, reﬂecting an inability to identify, test,
conﬁrm, and report many cases, especially mild cases.6 Recently,
Dawood et al. estimated 300 000 deaths during the ﬁrst year of
A(H1N1)pdm09 circulation.7 Miller et al. reported the results of a
large seroepidemiological survey in England to document the age-
speciﬁc prevalence of neutralizing antibodies to A(H1N1)pdm09
before and after the ﬁrst wave of the pandemic, to provide a direct
measure of the incidence of infection; they concluded that it was
approximately 2% at baseline and between 20% and 40% for
different age groups among children, but was not different in
adults.8 However, the impact of inﬂuenza during the spring andciety for Infectious Diseases. Open access under CC BY-NC-SA license.
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observed during the ﬁrst wave in the Southern Hemisphere.9
The ﬁrst outbreak of A(H1N1)pdm09 reached the metropolitan
area of Buenos Aires, inhabited by 14 million people, in May 2009,
and led to the highest mortality rates among patients conﬁrmed to
be infected with this virus in the Southern Hemisphere.10
This report describes a cross-sectional serological study from
one of the countries in the Southern Hemisphere where the ﬁrst
wave of circulation of the A(H1N1)pdm09 virus coincided with
seasonal inﬂuenza infections. Virus-speciﬁc antibody levels were
measured in community participants and health care workers
(HCWs) after this ﬁrst wave of infection. The prevalence was
estimated by measuring neutralizing antibodies to the
A(H1N1)pdm09 virus using pre-pandemic (baseline) and post-
pandemic serum samples.
2. Materials and methods
This study was performed during January and February 2010
(the summer season in Argentina) after the main wave of
A(H1N1)pdm09 infection had occurred in the country and before
the nationwide vaccination campaign for the A(H1N1)pdm09 virus
started in March 2010 (Figure 1).
This was a hospital-based population study. Two public
hospitals were involved in the study: Hospital de Nin˜os ‘‘Dr.
Ricardo Gutie´rrez’’, a pediatric hospital associated with the
Universidad de Buenos Aires, and Hospital de Clı´nicas ‘‘Jose´ de
San Martı´n’’, Universidad de Buenos Aires. The hospitals serve as
reference centers for pediatric and adult patient populations,
respectively.
2.1. Study population
The study population included otherwise healthy children <19
years old undergoing elective surgery who required routine
laboratory analyses at Hospital de Nin˜os ‘‘Dr. Ricardo Gutie´rrez’’,
and healthy adults and blood donors from Hospital de Clı´nicas
‘‘Jose´ de San Martı´n’’.
Subjects older than 1 year who agreed to participate in the
study and who provided written informed consent were included.Figure 1. The incidence of inﬂuenza in Argentina from week 13, 2009 to week 35, 2010. T
in 2009. In contrast to what happened in 2009, the incidence of A(H1N1)pdm09 in 2010 w
B. Reproduced with permission from Sistema de Vigilancia por Laboratorio (SIVILA-SNFor children aged <19 years, written informed consent was
provided by their parents or legal representatives.
In addition, blood samples were obtained from 40 healthy
HCWs, including physicians, nurses, administrative personnel, and
laboratory technicians who worked at the Hospital de Clı´nicas
during the pandemic, to compare the prevalence in this population
with the prevalence observed in the rest of the adult population
under study.
Subjects diagnosed with AIDS, those receiving chronic cortico-
steroid therapy (equivalent to meprednisone 20 mg/day for at
least 1 month), patients with active malignancies under therapy,
and organ transplant recipients undergoing immunosuppressive
therapy were excluded.
This study was conducted in accordance with the amended
Declaration of Helsinki and was approved by the institutional
review boards and ethics committees of both participating
hospitals (approval numbers 121109 and 161209 for Hospital de
Nin˜os ‘‘Dr. Ricardo Gutie´rrez’’ and Hospital de Clı´nicas ‘‘Jose´ de San
Martı´n’’, respectively).
2.2. Questionnaire
A questionnaire was completed to collect patient demographic
data and information on relevant past medical history, the
occurrence of suspected symptoms of inﬂuenza during the past
fall–winter season (May to October 2009) in the Southern
Hemisphere, history of seasonal inﬂuenza vaccination, household
contact with a suspected or conﬁrmed A(H1N1)pdm09 case, and
the use of antiviral and/or antibiotic medication during the
inﬂuenza season.
2.3. Specimen collection
For both adults and children, a 1.5-ml blood sample was drawn
for measurement of antibodies against the A(H1N1)pdm09 virus.
Serum samples were obtained by centrifugation for 10 min at
2500 rpm and stored at 20 8C. The analyses to determine the
antibody titers were performed by the Virology Department,
Instituto Nacional de Enfermedades Infecciosas – ANLIS, ‘‘Dr. C.G.
Malbra´n’’, Buenos Aires.he A(H1N1)pdm09 outbreak produced a peak of incidence that occurred at week 26
as very low. Instead, during 2010, the most prevalent inﬂuenza virus was inﬂuenza
VS), Direccio´n de Epidemiologı´a, Ministerio de Salud de la Nacio´n.
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Antibodies against the A(H1N1)pdm09 virus were detected
using the hemagglutination inhibition (HI) assay. Serum samples
were pre-treated with receptor destroying enzyme (RDE; Denka
Seiken Co. Ltd, Tokyo, Japan) at a 1:4 (vol/vol) dilution and
incubated overnight at 37 8C. The enzyme was inactivated by
heating at 56 8C for 30 min. The HI assay was performed according
to the standard protocol provided by the WHO Collaborating
Centre for Reference and Research on Inﬂuenza and the US Centers
for Disease Control and Prevention (CDC, Atlanta, USA).
Brieﬂy, serum samples were titrated in phosphate buffered
saline using two-fold dilutions from 1:10 to 1:1280 and incubated
with 25 ml (4 hemagglutinating units (HAU)) of b-propiolactone
(BPL)-inactivated A(H1N1)pdm09 antigen provided by the CDC.
Following 1 h of incubation, 25 ml of a 0.5% turkey red blood cell
suspension were added to each well.
When the serum sample presented non-speciﬁc agglutinins, 20
volumes of the serum were adsorbed with one volume of packed
turkey red blood cells. An A(H1N1)pdm09 reference sheep
antiserum provided with the CDC kit was included as a positive
control, and an inﬂuenza-negative sheep serum was used as a
negative control. The HI titer is the reciprocal of the last dilution of
antiserum that completely inhibits hemagglutination. It is
generally accepted that serum HI antibody titers of 40 are
associated with at least a 50% reduction in risk for infection or
disease from inﬂuenza viruses in human populations.11 Therefore,
an HI antibody titer 40 was considered a positive result.
2.5. Control population
A baseline level of prevalence of cross-reactive antibodies to the
A(H1N1)pdm09 virus before the virus was introduced into the
country was determined using serum samples collected as part of a
seroepidemiological study of viral hepatitis during 2007–2008
from individuals aged 1–73 years living in the same region.
2.6. Data analysis and statistics
The estimated sample size for a conﬁdence level of 95% was 384
participants, assuming a prevalence of 50%, a precision level of 5%,
and a half interval of 20%.
A descriptive analysis was performed. For categorical variables,
the Chi-square or Fisher’s exact test was used. For numerical data,
the Mann–Whitney test was performed. A p-value of <0.05 was
considered statistically signiﬁcant. The statistical package SPSS
Statistics version 17.0 (SPSS Inc., Chicago, IL, USA) was used for the
analyses.Table 1
Characteristics of the study population
Children (n = 150) Adults (n = 427)
Agea
Mean ( SD) 130.3 ( 57.7) 38.5 ( 14)
Median 136.5 35.5
Range 18–216 19–80
Gender
Female 85 (56.7%) 198 (46.6%)
Location
CABA 31 (20.7%) 161 (37.8%)
Suburban area 114 (76.0%) 260 (60.8%)
Interior regions of the country 5 (3.3%) 5 (1.2%)
Health care workers - 44 (10.3%)
SD, standard deviation; CABA, Ciudad Auto´noma de Buenos Aires.
a Age is expressed in months for children and in years for adults.3. Results
Serum samples collected from 577 people aged 18 months to 80
years were included in the study (Table 1). Overall, 28.9% (95%
conﬁdence interval (CI) 25–33%) of the study population had
seroprotective HI antibody levels to A(H1N1)pdm09 in January and
February 2010.
The proportion of people with seroprotection against the
A(H1N1)pdm09 virus varied with age (Figure 2). The seropreva-
lence was 58.0% (95% CI 49.7–66.2%) in children aged 1–18 years
and 18.7% (95% CI 14.9–22.5%) in adults (p < 0.001).
In children, seroprevalence increased according to age. From 12
to 59 months, 10/23 were seropositive (43.55%, 95% CI 21–65.9%);
from 60 to 119 months, 25/40 were seropositive (62.5%, 95% CI 46–
78%); from 120 to 179 months, 33/49 were seropositive (67.3%,
95% CI 53–81%); and from 180 to 216 months, 19/38 were
seropositive (50%, 95% CI 32–67%).
School-aged children, 5–18 years old, had the highest
seroprevalence and a signiﬁcant increase compared to the baseline
(p < 0.001). This was followed by pre-school children aged 1–4
years (p = 0.014).
Seroprevalence was lower among adults aged 19–39 years, with
a signiﬁcant increase compared to the baseline (p = 0.017). It was
even lower among those aged 40–59 years and among those aged
60 years. For the age groups 40–59 years and 60 years,
seroprevalence was not signiﬁcantly higher than the prevalence
found at baseline.
Data obtained using the questionnaire (Table 2) indicated that
in children, there was no statistically signiﬁcant difference in
seroprevalence by sex or location; however, in adults, men had a
signiﬁcantly higher seroprevalence than women. The seropreva-
lence among HCWs was not higher than the seroprevalence found
in the rest of the sampled adult population.
All of the enrolled subjects were asked about the occurrence of
symptoms of inﬂuenza-like illness during the fall–winter 2009
season. Recorded symptoms included a history of fever, sore throat
or hoarseness, nasal discharge or bleeding, dry or productive
cough, shortness of breath, intense muscle or joint pain, nausea or
vomiting, diarrhea, headache, and conjunctivitis. Only headache
was signiﬁcantly associated with seroprotection in both children
(p = 0.016) and adults (p = 0.020).
Interestingly, among children, a history of nausea or vomiting
showed a signiﬁcant inverse association with the presence of
protective titers of antibodies against A(H1N1)pdm09 (p = 0.040).
In children, no relevant past medical history was identiﬁed as a
risk factor for A(H1N1)pdm09 infection, including past neoplastic
disease, diabetes, asthma, or prematurity. None of the seropositive
children had possible or conﬁrmed exposure to this virus.
Among adults, current cigarette smoking was associated with
acquisition of the infection (p = 0.034). Past neoplastic disease,
diabetes, HIV positivity, any heart or lung disease, pregnancy
during 2009, and heavy drinking were not signiﬁcantly associated
with seroprotection. Among subjects who received oseltamivir
treatment during that inﬂuenza season, 75% had detectable
A(H1N1)pdm09 antibody titers (p = 0.006).
4. Discussion
In this study, we observed that overall seroprevalence of
antibodies against the A(H1N1)pdm09 virus for the population
attending one of two hospitals in the metropolitan area of Buenos
Aires was 29%. There was wide variation in the acquired
seroprotection level against the A(H1N1)pdm09 virus among
the different age groups. Seroprevalence in subjects aged 1–18
years was 58.0% (60% in school-aged children, 5–18 years), while it
was 18.7% in adults. Although this difference has been mentioned
Figure 2. The seroprevalence of A(H1N1)pdm09 and its variation among the different age groups compared with the baseline titers. Seroprevalence was 58% (95% CI 49.7–
66.2%) in children 1–18 years old and 18.7% (95% CI 14.9–22.5%) in adults (p < 0.001). Among children, the seroprevalence was 43.5% (95% CI 21–65.9%) in those aged 1–4
years and 60.6% (95% CI 51.7–69.5%) in school-aged children (5–18 years old); in both groups, the seroprevalence increased signiﬁcantly compared to the baseline. Among
adults 19–39 years of age, the seroprevalence was 24.9% (95% CI 19.4–30.4%), which was signiﬁcantly higher than the baseline. Among those aged 40–59 years old, the
seroprevalence was 9.7% (95% CI 4.3–15.1%), and among those aged 60 years, it was 8.1% (95% CI 0–18.3%). For these two groups, seroprevalence did not increase
signiﬁcantly compared to the baseline.
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pandemic, the prevalence found in this study is higher than the
ﬁgures reported previously.8,12 In a cross-sectional serological
survey performed in England, Miller et al. compared the prevalence
observed in serum samples taken in 2008 (before the ﬁrst wave of
A(H1N1)pdm09 infection) with serum samples taken in August
and September 2009 (after the ﬁrst wave of infection); they
observed a signiﬁcant increase in the HI titers for subjects between
0 and 24 years of age, but not in the older age groups.8 The
prevalence of positive HI serology they reported was about halfTable 2
Pandemic inﬂuenza A/H1N1 2009 seroprevalence by gender, location, and health care 
n Positiv
titer 
Gender
Children 
Female 85 49 
Male 65 38 
Adults 
Female 198 27 
Male 229 53 
Location
Children 
CABA 31 16 
Suburban area 114 69 
Inner of the country 5 2 
Adults 
CABA 161 26 
Suburban area 260 53 
Inner of the country 5 1 
Health care workers 
Yes 44 6 
No 383 74 
CI, conﬁdence interval; CABA, Ciudad Auto´noma de Buenos Aires.that reported here. This difference could be attributed to the
relatively mild characteristics of the ﬁrst wave of infection that
occurred in the spring season in the Northern Hemisphere, while a
more severe wave occurred during the fall and winter seasons in
the Southern Hemisphere.6 Higher attack rates during the
ﬁrst wave were reported in Australia, New Zealand, South Africa,
and South America.10 Bandaranayake et al. in New Zealand
measured the titers of neutralizing antibodies after the ﬁrst wave
of A(H1N1)pdm09 and compared pre-pandemic with post-
pandemic seroprevalence in non-vaccinated subjects in theworker status
e
40
Seroprevalence
% (95% CI)
p-Value
for group
1
57.6 (46.5–68.7)
58.5 (45.7–71.2)
0.013
13.6 (8.6–18.4)
23.2 (17.4–28.8)
0.690
51.6 (32.4–70.8)
60.5 (51.1–69.9)
40.0 (0–92.9)
0.552
16.1 (10.1–22.1)
20.3 (15.2–25.4)
20 (0–65.0)
0.421
13.6 (2.3–24.9)
19.3 (15.2–23.4)
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found an overall community seroprevalence of 26.7%; analyzing
the different age groups, they described a seroprevalence of 46.7%
in children aged 5–19 years, with a signiﬁcant increase from the
baseline, while in older adults aged 60 years, seroprevalence was
not different compared with the baseline. They also found, as we
did, that seroprevalence in HCWs was not different from that
observed in the general population. General hygiene measures
strictly established during the pandemic, as well as the use of post-
exposure prophylaxis, could explain this result. The lower
seroprevalence observed in children aged 5–19 years in the New
Zealand study compared with children aged 5–18 years in our
study suggests that a stronger impact of infection existed in
Argentina than in New Zealand.
In Argentina, Libster et al. performed a study of the burden of
the disease caused by the A(H1N1)pdm09 virus during an
expected second wave in a catchment population of 1.2 million
children. While there were 251 hospitalizations and 13 deaths
between May 1 and July 31, 2009, no pediatric hospitalizations
due to A(H1N1)pdm09 were identiﬁed in 2010 (p < 0.001).13
They attributed this absence of severe pediatric cases mainly to
the administration of the A(H1N1)pdm09 monovalent vaccine in
infants, children under 5 years of age, and older children with
high-risk medical conditions, as well as to the availability and
use of oseltamivir and to the effect of the 2009 outbreak leaving
natural immune protection. A similar study performed in New
Zealand in 2010 showed that there was a less severe impact of
A(H1N1)pdm09 in 2010 than that observed in 2009.14 Because
the vaccination campaigns in both countries during the ﬁrst
months of 2010 were similar, with coverage of approximately
25% of the population,14,15 the difference in attack rates is
probably more attributable to the higher attack rate observed in
Argentina during the winter in 2009, particularly in school-aged
children.
In our study, the seroprevalence was lower in adults, although it
remained signiﬁcantly higher than the baseline in people aged 19–
39 years. The seroprevalence was even lower among those aged
40–59 years and in those aged 60 years. For these last two groups,
seroprevalence was not signiﬁcantly higher than the prevalence
found at baseline.
Since 1981, the CDC has recommended that HCWs receive
vaccination against inﬂuenza in an effort to reduce transmission
of the virus to their vulnerable patients.16 It has been documented
that nurses from a staff cohort with a vaccination rate near null
were the likely source of devastating inﬂuenza outbreaks in a
neonatal unit17 and in a solid-transplant unit.18 In 2009, during
the A(H1N1)pdm09 pandemic, immunization was recommended
to HCWs, regardless of whether or not they had vulnerable
patients in their care, to protect themselves, their families, and
their patients from inﬂuenza. Comparing the seroprevalence of
A(H1N1)pdm09 found among the HCWs with the general
population, neither our study nor the one by Bandaranayake
et al. found a higher seroprevalence in HCWs.12 These ﬁndings
may reﬂect that transmission of A(H1N1)pdm09 occurred mainly
in the community, with a reduced transmission rate among
hospital admissions.
We found a signiﬁcantly higher seroprevalence in male adults
but not in male children. This may be due to a higher exposure rate
in adult males than in females because of mitigation measures
implemented during the pandemic, such as closing schools, duty
leave for pregnant women, and other guidelines that mainly
reduced the exposure of women.
Headache, both in children and in adults, was the only clinical
manifestation that was recalled by the seropositive individuals as
being present during the time of the outbreak in Buenos Aires, in
contrast with the usual ﬂu symptoms of high fever, respiratorysigns, and diarrhea in children. Interestingly, among children, a
history of nausea or vomiting showed a signiﬁcant inverse
association with the presence of protective titers of antibodies
against A(H1N1)pdm09, probably reﬂecting a gastrointestinal
illness rather than an inﬂuenza-like symptom.
In a case–control study of risk factors for hospitalization caused
by A(H1N1)pdm09, Ward et al. found smoking to be an
independent risk factor for hospitalization from this virus,19 which
is consistent with our ﬁndings of current smoking being associated
with the acquisition of this infection. In addition, Muscatello et al.
also found smoking to be an independent risk factor associated
with inﬂuenza-like illness during the 2009 winter epidemic of the
A(H1N1)pdm09 virus in New South Wales, Australia.20
The seroprevalence observed in the four subjects with reported
ingestion of oseltamivir during the time of the A(H1N1)pdm09
outbreak in Buenos Aires was 75%, which was signiﬁcantly higher
than in those who did not receive this antiviral therapy. The
relative lack of association with the majority of signs, symptoms,
and medical history expected to be found in a population with
serological positivity for inﬂuenza suggests that the spread of the
A(H1N1)pdm09 infection was often subclinical and could not be
recognized by those infected.
The present study has some limitations. While blood donors
contributed to the pool of sampled adults, the sampled population
of children only included those who were otherwise healthy and
undergoing elective surgery requiring blood tests. In addition, we
cannot exclude the possibility that the relatively small proportion
of HCWs in this study makes the comparison of their seropositivity
with that of the rest of the population less precise.
In conclusion, the seroprevalence of the A(H1N1)pdm09 virus
in the metropolitan area of Buenos Aires was high, likely due to
several factors, including the appearance of the infection during
the winter in the Southern Hemisphere and its simultaneous
introduction into different settings at the same time. The
seroprevalence was much higher in children, who constitute the
main age group responsible for spreading the infection due to their
having no pre-existing immunity against this novel virus.
Interestingly, headache was the only reported symptom by those
having the infection, and seroprevalence in HCWs was not higher
than that in the general population.
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